Form 4: PROCEPT BioRobotics Exec Sells Shares Under 10b5-1 Plan

PROCEPT BioRobotics EVP Alaleh Nouri sold common stock totaling 5,363 shares under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Alaleh Nouri, Executive Vice President, Chief Legal Officer, and Corporate Secretary of PROCEPT BioRobotics Corp (PRCT), reported transactions.
• Nouri sold 3,031 shares of common stock at a weighted average price of $25.8193 per share on March 19, 2026.
• These shares were sold in multiple transactions ranging from $25.025 to $26.020.
• Additionally, Nouri sold 2,332 shares of common stock at a weighted average price of $26.146 per share on March 19, 2026.
• These shares were sold in multiple transactions ranging from $26.025 to $26.450.
• The sales were executed pursuant to a Rule 10b5-1 trading plan adopted by Nouri on June 4, 2025.
• Following these transactions, Nouri beneficially owns 105,354 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The filing reports a routine insider stock sale executed under a pre-arranged Rule 10b5-1 trading plan, which typically does not signal new information about the company's performance or prospects.

Industry Context

StockSavvy.ai notes that insider stock sales, particularly when executed under a Rule 10b5-1 trading plan, are a common occurrence for executives managing personal finances, diversifying portfolios, or exercising vested equity. Such pre-arranged plans are designed to allow insiders to sell shares without being accused of trading on material non-public information.

Stakeholder Impact

• Shareholders may note the insider sale, but given it was executed under a Rule 10b5-1 plan, it is generally perceived as a pre-scheduled personal financial management event rather than a reflection of management's immediate outlook on the company's future.

Key Dates

Recommendation

The filing details a pre-scheduled insider stock sale by an executive, which is a routine event for executive compensation and personal financial management. It does not provide new information about PROCEPT BioRobotics Corp's operational performance, strategic direction, or financial health that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate as this disclosure alone does not alter the fundamental outlook for the stock.

Keywords

PROCEPT BioRobotics, PRCT, Alaleh Nouri, Insider Trading, Stock Sale, Form 4, Rule 10b5-1